Asterisk Flu powder, 15 g 10 pcs.

A combination drug.

Paracetamol is a non-narcotic analgesic, affecting the centers of pain and thermoregulation, has analgesic and antipyretic effects.

Pheniramine is a blocker of H1-histamine receptors, reduces rhinorrhea and lacrimation, eliminates spastic phenomena.

Phenylephrine is an adrenomimetic with moderate vasoconstrictor action (alpha1-adrenoreceptor stimulation).

Ascorbic acid is involved in the regulation of redox processes, carbohydrate metabolism, blood coagulation, tissue regeneration, the synthesis of steroid hormones, increases resistance to infection, reduces vascular permeability, reduces the need for vitamins B1, B2, A, E, folic acid, pantothenic acid.

It improves tolerance of paracetamol and prolongs its effects (associated with prolongation of T1/2).

Indications

Symptomatic treatment of “colds”, ARVI, incl. influenza (fever, pain, rhinorrhea).

Pharmacological effect

Combined drug.

Paracetamol is a non-narcotic analgesic, acting on the centers of pain and thermoregulation, and has an analgesic and antipyretic effect.

Pheniramine is a blocker of H1-histamine receptors, reduces rhinorrhea and lacrimation, eliminates spastic phenomena.

Phenylephrine is an adrenergic agonist with a moderate vasoconstrictor effect (stimulation of alpha1-adrenergic receptors).

Ascorbic acid is involved in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, and in the synthesis of steroid hormones; increases the body’s resistance to infections, reduces vascular permeability; reduces the need for vitamins B1, B2, A, E, folic acid, pantothenic acid.

Improves the tolerability of paracetamol and prolongs its effect (associated with prolongation of T1/2).

Special instructions

During the treatment period, it is necessary to refrain from drinking ethanol (hepatotoxicity may develop).

Impact on the ability to drive vehicles and operate machinery

It is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Paracetamol, Phenylephrine, Pheniramine, Ascorbic acid

Composition

1 pack contains:

Active substances:

paracetamol 325 mg,

pheniramine maleate 20 mg,

phenylephrine hydrochloride 10 mg,

ascorbic acid 50 mg,

Excipients:

povidone 25 mg,

mannitol 2 g,

calcium phosphate 30 mg,

sucrose 11.29 g,

citric acid 1 g,

sodium citrate 100 mg,

aspartame 10 mg,

orange flavoring,

raspberry or lemon 140 mg.

Contraindications

hypersensitivity;
children under 12 years of age;
phenylketonuria;
diabetes mellitus;
portal hypertension;
alcoholism;
renal failure;
pregnancy;
lactation period;
deficiency of glucose-6-phosphate dehydrogenase;
while taking tricyclic antidepressants, monoamine oxidase inhibitors (MAO), beta-blockers.

With caution

Congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), children under 15 years of age, angle-closure glaucoma, prostatic hyperplasia, severe atherosclerosis of the coronary arteries, arterial hypertension, liver and/or kidney failure, pheochromocytoma.

Side Effects

Allergic reactions (skin rash, itching, urticaria, angioedema), nausea, epigastric pain; anemia, thrombocytopenia, agranulocytosis.

Increased excitability, dizziness, increased blood pressure, difficulty falling asleep.

Mydriasis, accommodation paresis, increased intraocular pressure, dry mouth; urinary retention.

With long-term use in large doses – hepatotoxic effect, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia; nephrotoxicity (renal colic, glycosuria, interstitial nephritis, papillary necrosis).

Interaction

Enhances the effects of MAO inhibitors, sedatives, ethanol.

Ethanol enhances the sedative effect of pheniramine, which is part of the drug.

Pheniramine simultaneously with MAO inhibitors and furazolidone can lead to hypertensive crisis, agitation, and hyperpyrexia.

Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiazine derivatives increase the risk of developing urinary retention, dry mouth, and constipation.

Glucocorticosteroids (GCS) increase the risk of developing increased intraocular pressure.

Paracetamol reduces the effectiveness of uricosuric drugs and increases the effectiveness of indirect anticoagulants.

Tricyclic antidepressants enhance the sympathomimetic effect; simultaneous administration of halothane increases the risk of developing ventricular arrhythmia.

Reduces the hypotensive effect of guanethidine, which in turn enhances the alpha-adrenergic stimulating activity of phenylephrine.

Overdose

Symptoms (due to paracetamol): pale skin, decreased appetite, nausea, vomiting; hepatonecrosis (the severity of necrosis due to intoxication directly depends on the degree of overdose).

Toxic effects in adults are possible after taking more than 10-15 g of paracetamol: increased activity of liver transaminases, increased prothrombin time (12-48 hours after administration); a detailed clinical picture of liver damage appears after 1-6 days.

Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis).

Treatment: administration of SH-group donors and precursors for the synthesis of glutathione – methionine 8-9 hours after an overdose and N-acetylcysteine ​​after 12 hours.

The need for additional therapeutic measures (further administration of methionine, intravenous administration of N-acetylcysteine) is determined depending on the concentration of paracetamol in the blood, as well as the time elapsed after its administration.

Storage conditions

In a dry place, protected from light, at a temperature of 15 to 25°C.

Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Danafa Pharmaceutical Joint, Vietnam